TABLE 1.
Estimates of the Mean Reduction in SF-36/EQ-5D Domain Scores for Every Increase of 1 Point in the ZBPI Worst Pain Score
| Estimate | SE | t value | P | |
|---|---|---|---|---|
| ZOE-50/70 | ||||
| SF-36 | ||||
| PF | −1.50 | 0.141 | −10.65 | <0.0001 |
| RP | −2.00 | 0.197 | −10.18 | <0.0001 |
| BP | −3.63 | 0.181 | −20.11 | <0.0001 |
| GH | −0.84 | 0.113 | −7.44 | <0.0001 |
| VT | −1.64 | 0.155 | −10.58 | <0.0001 |
| SF | −2.07 | 0.186 | −11.13 | <0.0001 |
| RE | −1.36 | 0.198 | −6.87 | <0.0001 |
| MH | −1.52 | 0.134 | −11.37 | <0.0001 |
| EQ-5D | ||||
| Utility | −0.041 | 0.002 | −20.87 | <0.0001 |
| VAS | −1.94 | 0.136 | −14.30 | <0.0001 |
| ZOE-HSCT | ||||
| SF-36 | ||||
| PF | −1.57 | 0.307 | −5.11 | <0.0001 |
| RP | −2.35 | 0.387 | −6.06 | <0.0001 |
| BP | −3.78 | 0.367 | −10.30 | <0.0001 |
| GH | −0.60 | 0.203 | −2.93 | 0.036 |
| VT | −1.56 | 0.298 | −5.24 | <0.0001 |
| SF | −1.84 | 0.376 | −4.89 | <0.0001 |
| RE | −1.02 | 0.361 | −2.84 | 0.0048 |
| MH | −0.97 | 0.254 | −3.81 | 0.0002 |
| EQ-5D | ||||
| Utility | −0.044 | 0.0040 | −11.12 | <0.0001 |
| VAS | −2.31 | 0.271 | −8.55 | <0.0001 |
ZOE-50/70 combines participants from the ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) studies. ZOE-HSCT=participants from the ZOE-HSCT study (NCT01610414).
Estimates, SE, t values, and P-values obtained from the repeated measures, mixed effects model, adjusting for age and sex with random intercept and slope (ie, day of assessment) and ZBPI worst pain score included as a covariate. SF-36 domains and EQ-5D VAS are scored on a 0 to 100 scale, the range of the EQ-5D utility is (−0.5, 1). A higher score indicates a higher level of functioning/quality of life.
BP indicates Bodily Pain; EQ-5D, EuroQoL EQ-5D; GH, General Health; HSCT, hematopoietic stem cell transplantation; MH, Mental Health; PF, Physical Functioning; RE, Role Emotional; RP, Role Physical; SF, Social Functioning; SF-36, Short Form Health Survey 36; Utility, Utility Score; VAS, Visual Analog Scale; VT, Vitality; ZBPI, Zoster Brief Pain Inventory.